Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Locally Advanced Pancreatic Cancer Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The market size for locally advanced pancreatic cancer has experienced substantial growth in recent years. This market is projected to expand from $1.05 billion in 2025 to $1.16 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.5%. The historical growth of this market can be attributed to several factors, including the late-stage diagnosis of pancreatic cancer, limited surgical eligibility in locally advanced cases, a past reliance on gemcitabine-based chemotherapy, poor overall survival rates, and the increasing availability of hospital-based oncology care.
The market for locally advanced pancreatic cancer is projected to experience swift expansion in the coming years, anticipated to reach $1.71 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.2%. Factors contributing to this growth during the projection period include the broader application of combination therapy protocols, increased uptake of SBRT, greater investment in pancreatic cancer research, an intensified focus on individualized oncology care, and the expanded presence of sophisticated treatment centers. Key trends identified for the forecast timeframe encompass the more frequent utilization of combination chemotherapy regimens, the wider acceptance of neoadjuvant treatment methods, a heightened emphasis on reducing tumor size for surgical suitability, the broader use of radiation therapy for localized disease management, and a greater importance placed on collaborative treatment planning among different specialties.
Get A Free Sample Report With In-Depth Market Insights:
Locally Advanced Pancreatic Cancer Market Growth Momentum: What Factors Are Shaping Demand?
The anticipated expansion of the locally advanced pancreatic cancer markets is linked to a rise in tobacco use. Tobacco, derived from a plant, has leaves processed into items like cigarettes and cigars, and its addictive compound, nicotine, is associated with severe health problems, including cancer and heart disease. Several elements contribute to the increasing use of tobacco, such as its ready availability, low cost, promotional activities, social endorsement in certain regions, and smoking influenced by stress. Tobacco consumption is a major risk factor for developing locally advanced pancreatic cancer, as it contributes to a higher occurrence of pancreatic malignancies. For example, data from October 2024, shared by the Switzerland-based European Respiratory Society’s (ERS), a non-profit organization, indicated a notable surge in smoking prevalence among young individuals, showing that 22.5% of those surveyed smoked in 2022, a figure that climbed to 40.1% by 2024. Consequently, the expanding use of tobacco is fueling the growth of the locally advanced pancreatic cancer market.
Locally Advanced Pancreatic Cancer Market Breakdown By Product Type And Application
The locally advanced pancreatic cancer market covered in this report is segmented –
1) By Therapy: Chemotherapy, Radiation Therapy
2) By Route Of Administration: Oral, Injectables, Other Routes Of Administrations
3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users
Subsegments:
1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy
2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)
Locally Advanced Pancreatic Cancer Market Trends Redefining Industry Growth
Leading companies within the locally advanced pancreatic cancer market are concentrating on developing innovative products, such as orphan drugs, to enhance available treatment options, improve patient outcomes, and address the unmet medical needs associated with this aggressive disease. Orphan drugs are specialized medications crafted to treat rare conditions affecting a small subset of the population and are incentivized by regulatory authorities through benefits like tax reductions and market exclusivity to encourage their development. For instance, in January 2025, Actuate Therapeutics Inc., a US-based biopharmaceutical company, announced that its compound, Elraglusib, a novel GSK-3ß inhibitor, had been granted Orphan Drug Designation by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of pancreatic ductal adenocarcinoma (PDAC) (a potential type of locally advanced pancreatic cancer). This designation emphasizes its capacity to fill a critical void in managing this severe cancer, particularly following encouraging Phase 2 trial results demonstrating significant clinical improvements and anti-tumor effects in metastatic PDAC patients.
Locally Advanced Pancreatic Cancer Market Company Landscape And Competitive Strategy
Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck and Co Inc, Bristol Myers Squibb Company, AstraZeneca plc, AbbVie Inc, Novartis AG, GSK plc, Bayer AG, Eli Lilly and Company, Ipsen, Takeda Pharmaceutical Company Limited, Amgen Inc, Sanofi, Servier, NovoCure Limited, Halozyme Therapeutics, Clovis Oncology, Astellas Pharma, BeiGene
View The Full Locally Advanced Pancreatic Cancer Market Report:
Locally Advanced Pancreatic Cancer Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the locally advanced pancreatic cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
